Skip to Navigation Skip to Search Skip to Content
Search All Centers

An Update on Emerging Prostate Cancer Treatment Research

Read Transcript Download/Print Transcript

Published on March 5, 2019

What’s the latest in prostate cancer treatment news? How is the treatment landscape changing? Patient Power founder Andrew Schorr is joined by leading expert Dr. Maha Hussain, from Robert H. Lurie Comprehensive Cancer Center of Northwestern University, to discuss recent developments in clinical trial research and early indications of the promise of PARP inhibitors for prostate cancer. Watch now to find out more.

This is a Patient Empowerment Network program produced by Patient Power in partnership with Robert H. Lurie Comprehensive Cancer Center of Northwestern University. We thank Astellas, Clovis Oncology and Pfizer for their support. These organizations have no editorial control. Patient Power is solely responsible for program content.

Featuring

Partners

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Sponsors

Patient Empowerment Network

You might also like

Transcript | An Update on Emerging Prostate Cancer Treatment Research

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:                     

Okay, and just to be clear, we've gone through the range of approved therapies, is there anything that has been changing the landscape of late?

Dr. Hussain:               

Well, actually, this is a perfect question in terms of timing because, just recently, there was the European Society of Medical Oncology meeting, ESMO, and there's some very interesting information emerging from large clinical trials that were conducted in Europe demonstrating the potential value for adding radiation to the prostate area in men who have metastatic disease that is responsive to hormone treatment, but do not have a lot of cancer in their bone or lymph nodes, where, in fact, radiating the prostate is leading to a prolongation in terms of overall survival, life prolongation.   

I would encourage patients who might have just started hormone treatment for metastatic disease to discuss with their doctors whether they would be appropriate candidates for this type of approach, and certainly, there is a lot of research going on to better understand the biology of prostate cancer and how the cancer escapes the effect of the treatment to try to come up with better treatments to attack it. One of those, I guess, treatments are the PARP inhibitors.

Andrew Schorr:                     

All right. Let's talk about that. We're producing this program just days after the European Society of Medical Oncology meeting has happened in Munich Germany, and so news comes out about different approaches. PARP inhibitors that you just mentioned had promise, I believe, in ovarian cancer and now they think in breast cancer, so do they have a role in prostate cancer, Dr. Hussain?

Dr. Hussain:               

Well, I think my gut feeling is yes. PARP inhibitors have had a track record in ovarian and in breast cancer, and there are several FDA approvals in that regard. We began to discover that there are subgroups of men with prostate cancer who are potential candidates for PARP inhibitors, therapy, and literally, I, just about two days from now, will be giving a special lecture at the Prostate Cancer Foundation and have a table of all the PARP inhibitor trials that are going on in the US or in other parts of the world, and it's an amazing list of clinical trials.

Several of these trials are what I would consider registrational trials, and several of them have either approved or are undergoing approval. It'll be interesting to see, at the end of the day, the results because that's really what's gonna prove the principle, but the early indication would suggest that it is quite likely that prostate cancer will be one of those diseases that will benefit from PARP inhibition.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.